Sleep Apnea Biomarkers and Adherence to Continuous Positive Airway Pressure

Condition(s) studied

Investigational drug(s) / intervention(s)

Continuous Positive Airway Pressure: Continuous positive airway pressure prescribed as part of routine clinical care according to applicable clinical recommendations. The study does not assign the treatment or its settings.

Study summary

Obstructive sleep apnea (OSA) is commonly assessed using the apnea-hypopnea index, although this measure does not fully reflect cardiovascular risk or the physiological impact of the disease. Emerging biomarkers, including sleep apnea-specific hypoxic burden, pulse wave amplitude drop index, and heart rate response, may provide additional information on cardiovascular vulnerability.

This prospective multicenter observational study will investigate the association between these biomarkers, measured from the diagnostic sleep study, and adherence to continuous positive airway pressure (CPAP) therapy after three months. Symptoms, quality of life, clinical characteristics, and changes in biomarkers under continuous positive airway pressure will also be evaluated.

Eligibility

Primary outcome measure(s)

• Association Between Baseline Hypoxic Burden and CPAP Adherence at 3 Months — Baseline to 3 months after CPAP initiation
  Association between hypoxic burden measured during the baseline diagnostic sleep study and mean nightly CPAP use during the 30 days preceding the 3-month visit. CPAP adherence will also be categorized as less than 4 hours per night versus 4 hours or more per night.

Trial sites (1)

Other trials for the same condition